Feed aggregator

Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer

World Pharma News - Tue, 12/03/2019 - 13:00
A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows. The phase II trial found that over 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA genes responded well to treatment with the targeted drug olaparib.

AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada

World Pharma News - Tue, 12/03/2019 - 11:00
AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the US and Canada.

Astellas Buys Audentes for $3 Billion to Expand into Gene Therapy

Biospace news - Tue, 12/03/2019 - 02:00
The merger is an effort on the part of Astellas to strengthen its genetic medicine and gene therapy business.

Landing a Job Offer: Closing the Sale at the Interview

Biospace news - Tue, 12/03/2019 - 02:00
Experts differ on how direct job seekers should be in closing the sale. Some say candidates miss opportunities if they don’t come right out and ask for the job. Others say a hard sell doesn’t work in this situation.

Vaccines: A Healthcare Revolution and High Return on Investment

Biospace news - Tue, 12/03/2019 - 02:00
According to PhRMA, there are 264 vaccines in development to prevent and treat diseases. These include infectious diseases (137), cancer (101), allergies (10), autoimmune disease (8) and Alzheimer’s disease (4).

After Breakup with Sanofi, Lexicon Loses FDA CRL Appeal

Biospace news - Tue, 12/03/2019 - 02:00
In March, the FDA issued a Complete Response Letter for Zynquista as a treatment for type 1 diabetes.

Boston Biomedical Launches Cancer Research Alliance with Three Oncology Centers

Biospace news - Tue, 12/03/2019 - 02:00
Boston Biomedical announced it had launched an oncology research alliance with Columbia University, Harvard University and The Wistar Institute.

4 Ways to Amplify Your Job Search at the End of the Year

Biospace news - Tue, 12/03/2019 - 02:00
Here are a few ways to amplify your job search that can help you make significant progress.

Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute

Biospace news - Tue, 12/03/2019 - 02:00
In a filing with the court, Seattle Genetics claimed the right to arbitration to resolve the dispute with Daiichi Sankyo, as is required by the 2008 collaboration agreement.

AstraZeneca Sells off Seroquel Rights in U.S. and Canada

Biospace news - Tue, 12/03/2019 - 02:00
AstraZeneca inked a deal with Germany-based Cheplapharm Arzneimittel GmbH to sell the commercial rights to Seroquel and Seroquel XR in the U.S. and Canada.

Top 12 Biotech Companies Hiring Now

Biospace news - Tue, 12/03/2019 - 02:00
The end of the year is near, but don't slow down your job search. Check out the top companies who are looking for candidates like you right now!

FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions

World Pharma News - Mon, 12/02/2019 - 13:00
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2)

Investigational drugs reduce risk of death from Ebola virus disease

World Pharma News - Mon, 12/02/2019 - 11:00
The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC). The new report also shows that early diagnosis and treatment are associated with an increased likelihood of survival from EVD.

FDA Action Alert: Celgene, Amgen and Avadel

Biospace news - Mon, 12/02/2019 - 02:00
As we begin the final month of 2019, the U.S. Food and Drug Administration has several PDUFA dates to approve drug applications.

Using a Nanochip to Deliver Alzheimer’s Therapy to the Brain

Biospace news - Mon, 12/02/2019 - 02:00
There are many challenges to tackling neurological diseases like Alzheimer’s, but one is the difficulty in developing drugs that can cross the blood-brain barrier. Researchers may have found a way around that problem.

OncoSec Disputes Alpha Holdings' Claims Regarding Pending Acquisition from CGP

Biospace news - Mon, 12/02/2019 - 02:00
In its announcement today, OncoSec said the deal is pivotal to the company’s future. It claimed that South Korea-based Alpha Holdings, which has about 15% of the company’s stock, has been making “false and misleading statements” as it urges shareholders to oppose the deal.

Clinical Catch-Up: November 25-29

Biospace news - Mon, 12/02/2019 - 02:00
Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.

ASLAN Skyrockets on Preliminary Atopic Dermatitis Data

Biospace news - Mon, 12/02/2019 - 02:00
ASLAN announced positive preliminary data from the lowest dose cohort of its ongoing multiple ascending dose study of ASLAN004, which is aimed at moderate-to-severe atopic dermatitis.

Communicating Diversity and Inclusion: 5 Life Sciences Companies Who Are Nailing It

Biospace news - Mon, 12/02/2019 - 02:00
Here are five high-quality examples of major bio organizations’ efforts to showcase their commitment to providing a positive D&I work environment.

Following Two Novartis Deals, IFM Therapeutics Launches Third Subsidiary and Incubator

Biospace news - Mon, 12/02/2019 - 02:00
IFM Therapeutics is launching its third subsidiary this year with a focus on developing next-generation small molecule immunotherapies for inflammatory diseases and cancers.